Editing Parke-Davis (section)

== Products ==
<!--  [[Adrenaline (disambiguation)]] links to this section  -->

One of Parke-Davis' early products was an [[amylase]] isolated from ''[[Aspergillus oryzae]]'' by Dr. [[Takamine Jōkichi|Jōkichi Takamine]].<ref>Bennett, Joan and Yutaka Yamomoto. [http://www.deerland-enzymes.com/files/Dr_Jokichi%20Takamine_Bio.pdf  Dr. Jokichi Takamine: Japanese father of American Biotechnology] {{webarchive|url=https://web.archive.org/web/20060615080954/http://deerland-enzymes.com/files/Dr_Jokichi%20Takamine_Bio.pdf |date=2006-06-15 }}. ''Deerland Enzymes''.</ref> The enzyme was originally intended for use in [[distilleries]] but was more successfully marketed as "Taka-diastase" for [[dyspepsia]].

Also, Parke-Davis distributed [[Coley's toxins]], the first cancer vaccine, which was developed by William Coley to treat osteosarcoma.  Additionally, the company entered into a distribution agreement with the Inoculation Department of St Mary's (London) and distributed a number of vaccines for infectious diseases and even acne and cancer.<ref name="fleming">{{cite book| title=Penicillin Man: Alexander Fleming and the Antibiotic Revolution| first=Kevin| last=Brown| publisher=The History Press| date=December 2005| isbn=978-0750931533}}</ref>

Another of the company's products developed by Takamine was a pure form of adrenaline. The compound was patented in 1900 and trademarked as "Adrenalin." Because of the similarity of this name to "Adrenaline," the use of the alternative name "epinephrine" for generics was mandated in the United States and is used to this day. Parke-Davis filed a lawsuit against [[H. K. Mulford Company]] alleging infringement of its Adrenalin patents.  The ruling in favor of Parke-Davis by Judge [[Learned Hand]] is considered crucial to modern patent law.

Like [[Bayer]] with [[heroin]]; before the criminalization of [[cocaine]], the drug was sold by Parke-Davis in various forms, including cigarettes, powder, and even a cocaine mixture that could be injected directly into the user’s veins with the included needle. The company promised that its cocaine products would "supply the place of food, make the coward brave, the silent eloquent and ... render the sufferer insensitive to pain." In October 1915, [[Aleister Crowley]], author of ''[[Diary of a Drug Fiend]]'' and ''[[The Confessions of Aleister Crowley]]'', stopped by Parke-Davis in Detroit, where, according to Crowley, the cooperation was complete. "[They] were kind enough to interest themselves in my researches in [[Anhalonium lewinii]] (peyote) and made me some special preparations on the lines indicated by my experience which proved greatly superior to previous preparations."<ref>{{cite book |last=Sutin |first=Lawrence |title=Do What Thou Wilt: a life of Aleister Crowley |page=253 |date=September 14, 2000 |publisher=Macmillan |url=https://books.google.com/books?id=GdKvAwAAQBAJ&q=parke-davis |isbn=978-0312252434}}</ref> Parke-Davis also was the original manufacturer and patent holder of [[phencyclidine]] (PCP) which is currently listed as a Schedule II drug in the United States. It also developed Ketalar ([[ketamine]] hydrochloride), a general anesthetic and dissociative drug, in 1962.

Parke-Davis marketed the first widely available [[epilepsy]] treatment, [[Dilantin]], which was approved in 1939, although it discovered neither the compound nor the application on its own.<ref>[http://www.remarkablemedicine.com/Medicine/flaw2.html A Flaw in the System]. ''remarkablemedicine.com'' Accessed May 16, 2006.</ref>

In partnership with the Japanese firm [[Daiichi Sankyo Co.]] and the British firm [[Glaxo Wellcome]], Parke-Davis developed and marketed the anti-diabetic drug Rezulin ([[troglitazone]]) in the late 1990s. The drug was withdrawn in 2000 because of liver toxicity.

Parke-Davis developed the first bacterial [[vaccine]], and the company was thus known as a pioneer in the field of [[vaccinology]]. It was also among the five firms contracted to manufacture the original [[Jonas Salk|Salk]] killed-virus [[polio vaccine|vaccine]].<ref>Bayly, M. Beddow. The Story of the Salk Anti-Poliomyelitis Vaccine. 1956.</ref> A combination of the [[DPT vaccine|DPT]] and polio vaccines, called Quadrigen, was developed in 1954 and approved in 1959. Quadrigen was later removed from the market in 1968 after a series of lawsuits pertaining to adverse effects in vaccinated children.  Parke-Davis also produced the broad-spectrum antibiotic [[chloramphenicol]], which was a blockbuster product before the discovery of its association with [[aplastic anemia]].

Other products popularized by the company included [[anti-infective]]s and brands of [[combined oral contraceptive pill]]s.